Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2005 | 1 |
2007 | 1 |
2010 | 2 |
2023 | 1 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Validation of a new optical diagnosis training module to improve dysplasia characterization in inflammatory bowel disease: a multicenter international study.
Gastrointest Endosc. 2024 May;99(5):756-766.e4. doi: 10.1016/j.gie.2023.11.018. Epub 2023 Nov 21.
Gastrointest Endosc. 2024.
PMID: 37993058
Free article.
Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; PRECISE 2 Study Investigators.
Schreiber S, et al. Among authors: khaliq kareemi m.
N Engl J Med. 2007 Jul 19;357(3):239-50. doi: 10.1056/NEJMoa062897.
N Engl J Med. 2007.
PMID: 17634459
Free article.
Clinical Trial.
Item in Clipboard
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A; CDP870 Crohn's Disease Study Group.
Schreiber S, et al. Among authors: khaliq kareemi m.
Gastroenterology. 2005 Sep;129(3):807-18. doi: 10.1053/j.gastro.2005.06.064.
Gastroenterology. 2005.
PMID: 16143120
Clinical Trial.
Item in Clipboard
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators.
Lichtenstein GR, et al.
Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1.
Clin Gastroenterol Hepatol. 2010.
PMID: 20117244
Clinical Trial.
Item in Clipboard
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators.
Schreiber S, et al.
Am J Gastroenterol. 2010 Jul;105(7):1574-82. doi: 10.1038/ajg.2010.78. Epub 2010 Mar 16.
Am J Gastroenterol. 2010.
PMID: 20234346
Clinical Trial.
Item in Clipboard
Cite
Cite